Sichuan Baili Pharmaceutical Co., Ltd.
Works in Cardiovascular · Dermatology · ENT · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Oncology · Renal & urogenital · Respiratory · Women's health
Sichuan Baili Pharmaceutical Co., Ltd. is a clinical trial sponsor. It has 135 active clinical trials with 22,785 planned participants, across 12 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Pipeline · 135 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Sichuan Baili Pharmaceutical Co., Ltd
Sichuan Baili Pharmaceutical Co., Ltd is lead sponsor of 135 active clinical trials on ClinicalTrials.gov, with 22,785 planned participants, in Cardiovascular, Dermatology, ENT, GI & liver and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Sichuan Baili Pharmaceutical Co., Ltd; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Sichuan Baili Pharmaceutical Co., Ltd..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.